Loading…
PPCB
Propanc Biopharma, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 74346N800
$1.35-39.46%Price as of Aug 29, 18:51 UTC · updated once a day, after the close
Key metrics
- Market cap
- $3.08M
- P/E
- 0.0x
- Forward P/E
- —
- P/B
- 0.1x
- Dividend yield
- —
- Payout
- —
- EPS
- $355.60
- ROE
- -126.98%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 3.27
- 52-week high
- $77.49
- 52-week low
- $0.95
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
today you would have $0.48▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $13.41 | $0.01 | $0.60 | $30.00 | |
| P/B | — | 0.4x | — | — | — |
| EPS | -$371.25 | -$6,311.87 | -$781,709.75 | -$1,119,475.67 | |
| ROE | — | -423.72% | — | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| GNPXGenprex, Inc. | $3.67 | 0.1x | 0.1x | — | -203.86% | $3.01M |
| CALCCalciMedica, Inc. | $0.46 | — | 2.6x | — | -365.70% | $3.17M |
| MEDSDataMeds AI, Inc. | $0.96 | — | — | — | — | $2.94M |
| MTNBMatinas BioPharma Holdings, Inc. | $0.20 |
About the company
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
- 1
- Camberwell, Australia
Company description provided by Yahoo Finance.